Immunotherapy in GU Cancers Articles

FDA Approves Nivolumab/Ipilimumab for Frontline RCC
The FDA has approved the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma.
Standardization, Simplification Needed for Wider Adoption of Robotic Cystectomy
Amit Gupta, MD, discusses the superiority of robotic cystectomy compared with open cystectomies and its relevance in the current treatment landscape of bladder cancer.
European Panel Backs New Nivolumab Dosing Schedules
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended adding the option of a 4-week dosing schedule to the label for nivolumab for the treatment of patients with advanced melanoma and previously treated renal cell carcinoma (RCC). 
Expert Highlights Immunotherapy Success in GU Cancers
Ani S. Balmanoukian, MD, discusses developments in genitourinary malignancies with promising immunotherapy breakthroughs in renal cell carcinoma and urothelial carcinoma.
Chemotherapy May Be Vital to Long-Term Immunotherapy Efficacy in Bladder Cancer
Parminder Singh, MD, discusses the potential of immunotherapy, the importance of sequencing to avoid disease progression, and the use of chemotherapy and radiation therapy to reach an unmet need in muscle-invasive bladder cancer.
Figlin Discusses Optimizing Expanding Treatment Options in RCC
Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.
FDA Approves 4-Week Nivolumab Dosing Schedule
The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.
Optimal Sequencing Key to Capitalizing on RCC Advances
Thai H. Ho, MD, PhD, discusses treatment advances in first-line RCC and how biomarker development and optimal sequencing are critical next steps to building on recent breakthroughs.
DDR Alterations Associated With Increased Anti-PD-1/PD-L1  Activity in Bladder Cancer
Alterations in DNA damage response and repair genes were associated with an increased response to anti-PD-1/PD-L1 antibodies in patients with metastatic urothelial carcinoma. 
Immunotherapy Trials Offer Hope in Advanced Penile Cancer
Guru Sonpavde, MD, discusses the importance of clinical trial enrollment for patients with penile cancer. 
Publication Bottom Border
Border Publication